GlassScriptPhysician profile
Lauren L Eitzmann
NPI 1053993832
$1,619.31
in general payments reported to CMS, 2019-2025
21 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $472 · 2023: $330 · 2024: $221 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $443.08 | 2021-2025 | |
| Amgen INC. | $202.98 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $178.60 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $151.79 | 2021-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $104.69 | 2021-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $67.44 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.39 | 2021-2025 | |
| Electromed, INC. | $64.53 | 2021-2025 | Smartvest |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.13 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $43.11 | 2025 | Rexulti |
| Viatris Specialty LLC | $31.76 | 2025 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $30.18 | 2022 | |
| Mylan Specialty L.P. | $29.50 | 2024 | Yupelri |
| Pfizer INC. | $27.50 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $19.99 | 2024 | Austedo Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $18.57 | 2024 | Ingrezza |
| Corcept Therapeutics | $17.43 | 2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $16.33 | 2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.32 | 2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $14.21 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Eitzmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.